Aster Ridge Research
Event Intelligence Desk
Sign in
Aster Ridge Research · Memo
← Historical Board

BMY · SELL — Memo

···Event date 2024-07-26·Retrospective case · written 2026-06-28Live ResearchSource Set: completeInsight Q: 85CLOSED
BMY
Bristol-Myers Squibb Company
Beat-and-Raise Exhaustion
Signal
SELL
Confidence
66%
Horizon
6.4–12.6D
Est. Range
-6.8% to -3.9%
Materiality
74
Disloc.
72
Src. Conf.
80
Risk Level
Elevated
Invalidation
A reclaim of the post-print high on above-average volume, or a clean second confirming datapoint on the Growth Portfolio (a new approval or a beat-and-raise follow-through), invalidates the fade and downgrades to Monitoring.
§ INSIGHT

Non-Obvious Insight

The raise was real but low-quality: it leaned on cost-cut accruals and legacy-drug momentum whose expirations (Eliquis 2026, Opdivo 2028) are fixed and dominate the valuation. The pop priced a turnaround the disclosures didn't support — the dislocation was extrapolating one quarter over a dated cliff.
§ CALIB

Calibration & Timing

basis: event window based
Priced vs Not Priced
Q2 beat + guide raise priced via the pop; the Eliquis/Opdivo cliff and pre-launch Cobenfy not repriced
Thesis Window
5–12 trading sessions
Primary Holding Window
5–9 sessions
Reassessment Trigger
Reclaim of post-print high on volume, or a confirming Growth-Portfolio datapoint
Time Stop
12 sessions
Trim Zone
-4% to -6% (cover zone)
Continuation Confirmation
Failure to reclaim the post-print high; down-day volume
Failure Confirmation
Reclaim of post-print high on volume
Estimate Rationale
Range sized to a beat-and-raise fade into an unchanged cliff; −3.9% to −7.0% over 5–12 sessions.
§ ANALYTICS

Signal Analytics

Directional Pressure
70
Catalyst Strength
74
Market Reaction Quality
60
Narrative Dislocation
72
Source Confidence
80
Timing Quality
66
Risk Asymmetry
68
§01

Executive Summary

Bristol-Myers reported Q2 2024 on July 26: a clean beat (adj EPS $2.07 vs a consensus loss; revenue ~$12.2B, +11% FX-adj) and a full-year EPS guidance raise to $0.60–0.90, sending shares up ~8–11%. Desk reads the pop as a harvest of legacy-franchise momentum and one-time cost-cut credits, not a change in the structural setup: Eliquis and Opdivo (~45% of earnings) face hard 2026–2028 patent cliffs and Cobenfy is still pre-launch. Classifies BMY SELL over a 6.4–12.6D horizon to fade the beat-and-raise into the unchanged cliff math.
§02

Signal Classification

The SELL classification reflects: (1) catalyst materiality — a beat that does not move the dominant valuation variable (the Eliquis/Opdivo cliff); (2) narrative dislocation at 72 — the tape extrapolated one quarter of Growth-Portfolio strength over a known, dated revenue cliff; (3) source confidence at 80 (release, transcript, tier-1 coverage). The signal is the output. The reasoning is the edge.
§03

Market Misread

Consensus read the beat-and-raise as a turnaround confirmation. The reconciled record shows the raise leaned on cost-cut accruals and legacy-drug momentum (still ~54% of revenue) whose expirations are immutable; the Growth Portfolio is real but not yet scaled to offset a $13B+ Eliquis cliff. The market priced durability the disclosures did not support.
§04

Catalyst Chain

2024-07-25
Street enters the print cautious after a weak prior guide; expectations for a soft FY24.
Sets a low bar the beat clears, amplifying the relief pop.
2024-07-26
Q2 beat + FY24 EPS guide raised to $0.60–0.90; Growth Portfolio +21% FX-adj; stock pops ~8–11%.
The factual basis and the over-extrapolated bullish read.
2024-07-26
Call detail confirms Legacy Portfolio still ~54% of revenue with Revlimid already eroding.
The cliff math the pop ignores; defines the fade entry near $50.
§05

Evidence Chain

FY24 EPS guide raised on cost cuts + legacy momentum, not a structural revenue inflection.
Source
BMY Q2 release / call (Jul 26)
Confidence
+ raises conviction (primary source, quantified)
Implication
The raise is low-quality vs the cliff overhang.
Second-order
As the one-offs anniversary, EPS growth decelerates back toward the cliff trajectory.
Trade relevance
Core of the fade thesis.
Eliquis (EU exclusivity 2026) + Opdivo (2028) ~45% of earnings; Revlimid already declining post-2022 LOE.
Source
BioSpace / Drug Discovery News (pre-Jul 26)
Confidence
+ supportive (well-documented, dated)
Implication
Dominant value driver is the cliff, not the quarter.
Second-order
Multiple re-rates toward a patent-cliff story as the year progresses.
Trade relevance
Caps how far the pop can extend.
Cobenfy (schizophrenia) still pre-launch (PDUFA Sep 2024), zero Q2 revenue.
Source
Q2 transcript (Jul 26)
Confidence
~ neutral (optionality, not yet revenue)
Implication
The bull bridge over the cliff is unproven.
Second-order
Launch-execution risk keeps the offset speculative.
Trade relevance
Weakens the durability case behind the pop.
§06

Bull Case

A second confirming Growth-Portfolio datapoint (a new approval or a clean beat-and-raise follow-through), or constructive Cobenfy launch signals, would lift materiality and invalidate the fade — cover.
§07

Bear Case

Crowded value/turnaround positioning unwinds as focus returns to the cliff; a soft H2 sales-to-users print or pricing/policy headlines could extend the decline beyond the range. Tactical fade against a cheap, high-yield name — respect the invalidation.
§08

Invalidation Logic

A reclaim of the post-print high on above-average volume, or a clean second confirming datapoint on the Growth Portfolio (a new approval or a beat-and-raise follow-through), invalidates the fade and downgrades to Monitoring.
§09

Timing / Exit Conditions

Cover into a sharp flush or at the lower bound of the range; reassess on a reclaim of the post-print high. Cover zone −6.8% to −3.9%; this is a sentiment-fade, not a structural short.
§10

Source Review

Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs
Publisher
CNBC
Date
2024-07-26
Relevance
95
Materiality
78
Reason
Earnings-day beat + guide raise; the bullish read.
Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
Publisher
Business Wire
Date
2024-07-26
Relevance
96
Materiality
80
Reason
Primary release: segment revenue + guidance detail.
Bristol Myers Squibb (BMY) Q2 2024 Earnings Call Transcript
Publisher
The Motley Fool
Date
2024-07-26
Relevance
90
Materiality
74
Reason
Call verbatim: Growth vs Legacy split, cost cuts.
Bristol Myers Raises 2024 Profit Forecast on New Drug Demand
Publisher
Bloomberg
Date
2024-07-26
Relevance
88
Materiality
72
Reason
Confirms the raise framing and demand narrative.
Bristol-Myers Squibb (BMY) Q2 2024 Earnings Call Transcript
Publisher
Seeking Alpha
Date
2024-07-26
Relevance
84
Materiality
68
Reason
Secondary transcript for cross-check.
Bristol Myers Beats Q2 Earnings and Sales, Raises '24 View
Publisher
Nasdaq / Zacks
Date
2024-07-26
Relevance
80
Materiality
64
Reason
Sell-side framing of the beat.
Bristol Myers Squibb Witnesses Strong Demand For 'Newer Drugs' As Q2 Beats
Publisher
Yahoo Finance
Date
2024-07-26
Relevance
78
Materiality
62
Reason
Growth Portfolio demand detail.
5 Pharma Powerhouses Facing Massive Patent Cliffs
Publisher
BioSpace
Date
2024-06-18
Relevance
82
Materiality
72
Reason
Eliquis 2026 / Opdivo 2028 cliff magnitude.
Blockbuster drugs face a massive patent cliff in 2026
Publisher
Drug Discovery News
Date
2024-05-30
Relevance
76
Materiality
66
Reason
Independent cliff documentation.
Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)
Publisher
Yahoo Finance
Date
2024-06-20
Relevance
74
Materiality
64
Reason
BMY-specific cliff overhang pre-print.
§11

Analyst Notes

Desk note: a tactical fade of a beat-and-raise into an unchanged patent-cliff setup — not a call against the franchise. The edge is that one quarter cannot reprice a $13B+ Eliquis cliff; discipline at the invalidation is the trade. Treat Cobenfy optionality as a confirming, not initiating, variable.
§ Disclosure

This memo is impersonal research and analytical opinion published for general circulation. It is not investment advice, not a recommendation, and not an offer or solicitation to buy or sell any security. Signals, estimates, and return ranges are analytical opinions and forward-looking judgments — not guarantees, predictions, or a record of past performance. They are conditional on the stated invalidation levels and assumptions and may be wrong. Aster Ridge Research is not a registered investment adviser or broker-dealer and provides no individualized advice. You are solely responsible for your own decisions and should consult a licensed professional regarding your particular circumstances.

Aster Ridge Research is an independent research publication of general and impersonal circulation. It is not investment advice and creates no advisory or fiduciary relationship. No performance is promised or implied. Conduct your own due diligence and consult a licensed professional before acting.

A public note builds on this memo — a longer, plain-language analysis of the same classification.
Read the public note →